TS
DRTX

Thomas Steyer’s DURATA THERAPEUTICS INC COM STK (DE) DRTX Stock Holding History

Thomas Steyer’s Portfolio DRTX Stock Details DRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,000
Closed -$216K – 89
2013
Q2 		$216K Buy
+30,000
New +$220K ﹤0.01% 82

Other funds holding DRTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thomas Steyer's DRTX Position: Q3 2013 in Review

Thomas Steyer sold out of DURATA THERAPEUTICS INC COM STK (DE) (DRTX) in Q3 2013, closing a stake of 30,000 shares — an estimated $216K sold.

Thomas Steyer first reported a position in DRTX in Q2 2013 and held it in 1 quarter. The position peaked at $216K in Q2 2013. 48 funds tracked by Wall St. Rank hold DRTX as of Q3 2013.

  • Thomas Steyer reported no remaining DURATA THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Thomas Steyer sold 30,000 DURATA THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $216K.
  • Thomas Steyer first reported a position in DURATA THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Thomas Steyer's DURATA THERAPEUTICS INC COM STK (DE) position peaked at $216K in Q2 2013.
  • 48 funds tracked by Wall St. Rank held DURATA THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Farallon Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.